Advances of malignant pleural mesothelioma

VernacularTitle:恶性胸膜间皮瘤的研究进展
Author: Xinshu WU ; Xiaogang ZHAO ; Licun WU ; Bo CONG
Publication Type:Journal Article
Keywords: Mesothelioma; Therapy; Immune system; Hematology
From: Journal of International Oncology 2015;(6):462-465
CountryChina
Language:Chinese
Abstract: Malignant pleural mesothelioma (MPM)is a malignant cancer originated from pleural meso-thelial cell.The diagnosis of MPMis based on biopsy of pleura and immunohistochemistry.The current treat-ment of MPM is multimodality therapy including surgery,radiotherapy,chemotherapy and immunotherapy. There are two major surgical procedures:extrapleural pneumonectomy and pleurectomy/decortication.The main of radiotherapy is three-dimensional conformal radiotherapy.Cisplatinum combined with pemetrexed is the first-line chemotherapy for the patients with MPM.The principal targets for immunotherapy include regulatory T cells,cytotoxic T lymphocyte-associated antigen-4 and PD-1 .